scholarly journals Downregulated expression of human leukocyte antigen class I heavy chain is associated with poor prognosis in non‑small‑cell lung cancer

2019 ◽  
Author(s):  
Kazuomi Ichinokawa ◽  
Yoshitsugu Nakanishi ◽  
Yasuhiro Hida ◽  
Takahiro Tsuchikawa ◽  
Tatsuya Kato ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Human Leukocyte Antigen ◽  
Small Cell Lung Cancer ◽  
Heavy Chain ◽  
Poor Prognosis ◽  
Human Leukocyte Antigen Class ◽  
Human Leukocyte ◽  
Small Cell ◽  
Small Cell Lung ◽  
Leukocyte Antigen

Human leukocyte antigen (HLA) B44 supertype and immunotherapy outcomes in non-small cell lung cancer (NSCLC).

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 3026-3026
Author(s):  
Henry Lu ◽  
Amy Lauren Cummings ◽  
Jonathan Wade Goldman ◽  
Aaron Elliott Lisberg ◽  
Siwen Hu-Lieskovan ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Human Leukocyte Antigen ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Human Leukocyte ◽  
Small Cell ◽  
Small Cell Lung ◽  
Leukocyte Antigen

scholarly journals Distinctive germline expression of class I human leukocyte antigen (HLA) alleles and DRB1 heterozygosis predict the outcome of patients with non-small cell lung cancer receiving PD-1/PD-L1 immune checkpoint blockade

2020 ◽  
Vol 8 (1) ◽  
pp. e000733 ◽  
Author(s):  
Pierpaolo Correale ◽  
Rita Emilena Saladino ◽  
Diana Giannarelli ◽  
Rocco Giannicola ◽  
Rita Agostino ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adverse Events ◽  
Human Leukocyte Antigen ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Human Leukocyte ◽  
Small Cell ◽  
Class I ◽  
Small Cell Lung ◽  
Leukocyte Antigen

BackgroundNivolumab is a human monoclonal antibody against programmed cell death receptor-1 (PD-1) able to rescue quiescent tumor infiltrating cytotoxic T lymphocytes (CTLs) restoring their ability to kill target cells expressing specific tumor antigen-derived epitope peptides bound to homologue human leukocyte antigen (HLA) molecules. Nivolumab is currently an active but expensive therapeutic agent for metastatic non-small cell lung cancer (mNSCLC), producing, in some cases, immune-related adverse events (irAEs). At the present, no reliable biomarkers have been validated to predict either treatment response or adverse events in treated patients.MethodsWe performed a retrospective multi-institutional analysis including 119 patients with mNSCLC who received PD-1 blockade since November 2015 to investigate the predictive role of germinal class I HLA and DRB1 genotype. We investigated the correlation among patients’ outcome and irAEs frequency with specific HLA A, B, C and DRB1 alleles by reverse sequence-specific oligonucleotide (SSO) DNA typing.ResultsA poor outcome in patients negative for the expression of two most frequent HLA-A alleles was detected (HLA: HLA-A*01 and or A*02; progression-free survival (PFS): 7.5 (2.8 to 12.2) vs 15.9 (0 to 39.2) months, p=0.01). In particular, HLA-A*01-positive patients showed a prolonged PFS of 22.6 (10.2 to 35.0) and overall survival (OS) of 30.8 (7.7 to 53.9) months, respectively. We also reported that HLA-A and DRB1 locus heterozygosis (het) were correlated to a worse OS if we considered het in the locus A; in reverse, long survival was correlated to het in DRB1.ConclusionsThis study demonstrate that class I and II HLA allele characterization to define tumor immunogenicity has relevant implications in predicting nivolumab efficacy in mNSCLC and provide the rationale for further prospective trials of cancer immunotherapy.

scholarly journals Human leukocyte antigen(HLA)-Ggene polymorphism in patients with non-small cell lung cancer

2015 ◽  
Vol 6 (5) ◽  
pp. 613-619 ◽  
Author(s):  
Aneta Kowal ◽  
Andrzej Wiśniewski ◽  
Piotr Kuśnierczyk ◽  
Renata Jankowska
Keyword(s):  
Lung Cancer ◽  
Human Leukocyte Antigen ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Human Leukocyte ◽  
Small Cell ◽  
Small Cell Lung ◽  
Leukocyte Antigen
Sign in / Sign up

Export Citation Format

Share Document